Sun Pharma Gets CDSCO Panel Nod For Alfuzosin-Tadalafil FDC Post-Marketing Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-08-10 07:00 GMT | Update On 2025-08-10 07:00 GMT

New Delhi: Drugmaker Sun Pharmaceutical Laboratories Ltd has been granted conditional approval by the Subject Expert Committee (SEC), under the Central Drugs Standard Control Organisation (CDSCO), to conduct an Active Post Marketing Surveillance (PMS) study of its fixed-dose combination (FDC) drug: Alfuzosin Hydrochloride IP (ER) 10 mg + Tadalafil IP 5 mg uncoated bilayer tablet.

This approval came during the 6th SEC (Urology) meeting held on 22nd July 2025, where the firm presented its Active PMS protocol as required under Form CT-23 dated 25.04.2025.

Following detailed deliberation, the committee recommended the study with specific modifications, stating, "The ED score should be 22 instead of 25 in inclusion criteria. The inclusion criteria should include the patients having the Prostate volume of less than or equal to 60mL. The indication mentioned in the protocol should be in line with the permission granted in Form CT-23."

The SEC further directed that a revised Active PMS protocol incorporating these changes must be submitted to CDSCO for review. Upon approval, the firm must also submit the Active PMS report for further examination by the committee.

The fixed-dose combination combines Alfuzosin, an alpha-blocker that relaxes the muscles in the prostate and bladder, and Tadalafil, a phosphodiesterase-5 (PDE5) inhibitor believed to improve urinary symptoms in benign prostatic hyperplasia (BPH) patients.

Also Read: NPPA Caps Prices of Ipratropium, Sodium Nitroprusside, Two Other Essential Drugs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sun Pharma Gets CDSCO Panel Nod For Alfuzosin-Tadalafil FDC Post-Marketing Study

Similar News

Zydus Gets CDSCO Panel Nod for Phase III Trial of Dextromethorphan, Phenylephrine Cough Syrup FDC

Zydus Lifesciences Secures CDSCO Panel Approval for Usnoflast Capsule Interaction Study

CDSCO Flags MSD Pharma's Cancer Drug Trial Over Indian Representation, Control Arm

MSD Pharma gets CDSCO panel nod for New Indications of Pembrolizumab in India

CDSCO Panel Directs Malik Lifesciences to Revise Phase III Trial Protocol for Tamsulosin, Dutasteride, Tadalafil FDC

MSN Lab gets CDSCO panel nod for Phase IV CT of Tofacitinib Tablets 10 mg

SEC Recommends Phase III Trial of MSN Labs' Vibegron Against Mirabegron in Overactive Bladder

Not All Combipacks Are New Drugs: CDSCO Defines Approval Rules for Lyophilized Injections